OMALIZUMAB (Xolair) prior authorization at Premera Blue Cross
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Premera Blue Cross requires Anti-IgE prior-authorization documentation for OMALIZUMAB (Xolair): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Premera Blue Cross reviews OMALIZUMAB (Xolair) prior authorizations against its medical policy for Anti-IgE. Premera Blue Cross-specific context: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Anti-IgE
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Premera Blue Cross's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- WA-specific mental health parity violations
- Step therapy via Express Scripts
- Out-of-network reductions
- Specialty drug prior auth
OMALIZUMAB (Xolair)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- IgE level thresholds (30-1500 IU/mL) for asthma indication
- Indication restriction (asthma vs CIU vs nasal polyps vs food allergy)
- Step therapy requiring trial of inhaled corticosteroid + LABA first
Brand: Xolair. Anti-IgE monoclonal antibody. FDA-approved for moderate-to-severe persistent allergic asthma, chronic idiopathic urticaria, nasal polyps, and food allergy IgE-mediated (February 2024 — first FDA-approved drug to reduce allergic reactions to multiple foods).
Manufacturer patient-assistance program: Genentech Access Solutions — relevant when a Premera Blue Cross denial sticks and the patient needs bridge access while appealing.
How Premera Blue Cross approaches Biologic drugs (mAbs and biosimilars) PAs
For OMALIZUMAB (XOLAIR), check whether the current Premera Blue Cross Biologic drugs (mAbs and biosimilars) policy cites step therapy via express scripts or specialty drug prior auth. Pharmacy-benefit review for OMALIZUMAB (XOLAIR) at Premera Blue Cross is routed through Express Scripts. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Premera Blue Cross; if denied, use the filing date and route printed on that denial notice. Premera Blue Cross's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Premera Blue Cross is domiciled in WA, so unresolved appeals escalate to the WA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.premera.com/wa/provider) with the same packet plus an applicable, current clinical source supporting OMALIZUMAB (Xolair)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Premera Blue Cross denial on DenialHelp.
Contact Premera Blue Cross
- Provider portal: https://www.premera.com/wa/provider
Frequently asked questions
What documentation does Premera Blue Cross need for OMALIZUMAB (Xolair) prior auth?
Premera Blue Cross's typical PA packet for OMALIZUMAB (Xolair): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Anti-IgE, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Premera Blue Cross?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for OMALIZUMAB (Xolair) at Premera Blue Cross?
Preparation scenarios to check against the current notice and policy include: WA-specific mental health parity violations; Step therapy via Express Scripts; Out-of-network reductions. These are not measured frequency claims. For OMALIZUMAB (Xolair), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
What prior failures does Premera Blue Cross typically require before approving OMALIZUMAB (XOLAIR)?
Premera Blue Cross's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For OMALIZUMAB (XOLAIR), attach the specific disease-activity instrument Premera Blue Cross accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Express Scripts. External-review escalation for Premera Blue Cross fully-insured policies sits with the WA insurance department.
How do I prep for a peer-to-peer with Premera Blue Cross on OMALIZUMAB (Xolair)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the OMALIZUMAB (Xolair) PA packet
Open ApprovalHelp — generate a OMALIZUMAB (Xolair) prior-auth packet tailored to Premera Blue Cross's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com